Genus non-exec bulks up stake

Professor Barry Furr, a non-executive director at the animal breeding technology group Genus, has spent £30,000 more than doubling his stake in the animal breeding company, the firm confirmed today.He bought 5,000 shares at 600p a time and now has 8,000.Furr, a former chief scientist for the drug giant AstraZeneca, bought his initial stake of 3,000 shares at 680p a time in October.Genus sells breeding technology products to livestock and farmers.Top Director BuysVitec Group (VTC) Director name: Mr Stephen BirdAmount purchased: 25,000 @ 245.40p Value: £61,350Genus (GNS) Director name: Professor Barry FurrAmount purchased: 5,000 @ 600.00p Value: £30,000Homeserve (HSV) Director name: Mr Andrew SibbaldAmount purchased: 2,000 @ 1,244.00p Value: £24,880Imperial Innovations (IVO) Director name: Dr David C AllenAmount purchased: 4,313 @ 345.00p Value: £14,880Top Director SellsDechra Pharmaceuticals (DPH) Director name: Mr Ian PageAmount sold: 100,000 @ 410.00p Value: £410,000 Genus